The antiviral effects of a MEK1/2 inhibitor promote tumor regression in a preclinical model of human papillomavirus infection-induced tumorigenesis

  1. Adrian J. Luna
  2. Jesse M. Young
  3. Rosa T. Sterk
  4. Virginie Bondu
  5. Fred A. Schultz
  6. Donna F. Kusewitt
  7. Huining Kang
  8. Michelle A. Ozbun

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.antiviral.2023.105667
  2. preLights

    Excerpt

    How to fight HPV-induced cancer? In this preprint, Luna et al. investigated this possibility by testing two clinically approved drugs to stop HPV at its early replication stage.

  3. Version published to 10.1101/2023.03.14.532042v2 on bioRxiv
  4. Version published to 10.1101/2023.03.14.532042v1 on bioRxiv